This book provides the first comprehensive overview of a new scientific discipline termed Geroscience. Geroscience examines the molecular and cellular mechanisms that might explain why aging is the main risk factor for most chronic diseases affecting the elderly population. Over the past few decades, researchers have made impressive progress in understanding the genetics, biology and physiology of aging. This book presents vital research that can help readers to better understand how aging is a critical malleable risk factor in most chronic diseases, which, in turn, could lead to interventions that can help increase a healthy lifespan, or ‘healthspan.’ The book begins with an analysis of the Geroscience hypothesis, as well as the epidemiological underpinnings that define aging as a candidate main risk factor for most chronic diseases. Next, each chapter focuses on one particular disease, or group of diseases, with an emphasis on how basic molecular and cellular biology might explain why aging is a major risk factor for it. Coverage in the book includes: cancer, cardiovascular disease, dementias, stroke, Parkinson's and Alzheimer’s diseases, osteoporosis, arthritis, diabetes asthma, emphysema, kidney disease, vision impairment, and AIDS/HIV. It finishes with a chapter on pain in the elderly and an overview of future steps needed to bring the newly acquired knowledge into the clinic and the public at large.

"Aging affects us all and is characterized not only by increasing frailty but by increased susceptibility to conditions such as Alzheimer's, cardiovascular disease, and cancer. We are gaining an increasing understanding of the molecular mechanisms underlying aging, however, and uncovering clues to how life may be prolonged. This book examines the biological basis of aging and research into strategies that may extend lifespan"--

Older aged adults face many adversities over the later life course. This edited volume will address the ways in which seniors bounce back from different types and combinations of adversity – termed “resilience”. While research has been accumulating that identifies inherent abilities and external resources needed to adapt and navigate stress-inducing experiences among aging and older adults, gaps remain in understanding the unique elements and processes of resilience. A series of chapters included in this book will address several overarching questions: why do some older individuals/families/communities adapt to adversity better than others; what are modifiable behavioral protective/risk factors related to resilience; and how can we foster resilience at the individual/community level and which approaches show the most promise? The spectrum of aging-related challenges and responses addressed in this book include: mental health; physical/functional health problems; multimorbidity; socio-economic deprivation; social isolation and loneliness; cultural dimensions of loneliness; housing/homelessness problems; and environmental disasters. This book presents cutting-edge science at the conceptual, methodological, empirical and practice levels applied to emerging resilience sub-fields in gerontology. It will also present potential areas of future research, policy and practice linked to these areas. During a period of the most rapid population aging in the US, Canada and many other nations, coupled with heightened global socio-political change, extending our knowledge of resilience will help society to make important adjustments to maximize health and wellness of older individuals. Supporting and enhancing resilience through technological, social and/or community-level advances in geroscience will help those facing adversity to thrive by harnessing, stretching, and leveraging a wide array of potential resources. The promotion of healthier older populations has far-reaching consequences for health care and social/community support systems, both in terms of public health including pandemic response, and the development and implementation of innovations in treatment and practice guidelines.

Anti-Aging Pharmacology provides an overview of current research aimed at the pharmacological modulation of aging, including a discussion of the growing number of novel drug classes with promising anti-aging potential. The aging process is the main risk factor for all chronic diseases affecting the elderly. With lifespans extending across the globe, these chronic diseases are placing a larger burden on individuals and health care systems. Therefore, slowing down the aging rate could be more effective in delaying aging-associated chronic disorders than combating them one by one, which is the conventional approach in a current disease-based pharmacological paradigm. This book contains the work of the world's leading researchers in the field, including sections on the conceptual and methodological background of anti-aging pharmacology, the basic classes of anti-aging drugs, phytochemicals, outcomes of anti-aging developments and future directions. This book will be of interest to a wide audience, ranging from pharmacologists, medicinal chemists and academic researchers in gerontology, biomedical sciences and those in medical practice. - Includes updated information about current developments in anti-aging pharmacology - Offers practical advice on the applicability of certain healthspan-promoting medications - Discusses potential challenges related to the translation of anti-aging drugs in clinical practice

How do some people avoid the slowing down, deteriorating, and weakening that plagues many of their peers decades earlier? Are they just lucky? Or do they know something the rest of us don’t? Is it possible to grow older without getting sicker? What if you could look and feel fifty through your eighties and nineties? Founder of the Institute for Aging Research at the Albert Einstein College of Medicine and one of the leading pioneers of longevity research, Dr. Nir Barzilai’s life’s work is tackling the challenges of aging to delay and prevent the onset of all age-related diseases including “the big four”: diabetes, cancer, heart disease, and Alzheimer’s. One of Dr. Barzilai’s most fascinating studies features volunteers that include 750 SuperAgers—individuals who maintain active lives well into their nineties and even beyond—and, more importantly, who reached that ripe old age never having experienced cardiovascular disease, cancer, diabetes, or cognitive decline. In Age Later, Dr. Barzilai reveals the secrets his team has unlocked about SuperAgers and the scientific discoveries that show we can mimic some of their natural resistance to the aging process. This eye-opening and inspirational book will help you think of aging not as a certainty, but as a phenomenon—like many other diseases and misfortunes—that can be targeted, improved, and even cured.

Recent studies have indicated that epigenetic processes may play a major role in both cellular and organismal aging. These epigenetic processes include not only DNA methylation and histone modifications, but also extend to many other epigenetic mediators such as the polycomb group proteins, chromosomal position effects, and noncoding RNA. The topics of this book range from fundamental changes in DNA methylation in aging to the most recent research on intervention into epigenetic modifications to modulate the aging process. The major topics of epigenetics and aging covered in this book are: 1) DNA methylation and histone modifications in aging; 2) Other epigenetic processes and aging; 3) Impact of epigenetics on aging; 4) Epigenetics of age-related diseases; 5) Epigenetic interventions and aging: and 6) Future directions in epigenetic aging research. The most studied of epigenetic processes, DNA methylation, has been associated with cellular aging and aging of organisms for many years. It is now apparent that both global and gene-specific alterations occur not only in DNA methylation during aging, but also in several histone alterations. Many epigenetic alterations can have an impact on aging processes such as stem cell aging, control of telomerase, modifications of telomeres, and epigenetic drift can impact the aging process as evident in the recent studies of aging monozygotic twins. Numerous age-related diseases are affected by epigenetic mechanisms. For example, recent studies have shown that DNA methylation is altered in Alzheimer’s disease and autoimmunity. Other prevalent diseases that have been associated with age-related epigenetic changes include cancer and diabetes. Paternal age and epigenetic changes appear to have an effect on schizophrenia and epigenetic silencing has been associated with several of the progeroid syndromes of premature aging. Moreover, the impact of dietary or drug intervention into epigenetic processes as they affect normal aging or age-related diseases is becoming increasingly feasible.

The 2nd World Congress on Genetics, Geriatrics and Neurodegenerative Disease Research (GeNeDis 2016), will focus on recent advances in geriatrics and neurodegeneration, ranging from basic science to clinical and pharmaceutical developments and will provide an international focum for the latest scientific discoveries, medical practices, and care initiatives. Advances information technologies will be discussed along with their implications for various research, implementation, and policy concerns. In addition, the conference will address European and global issues in the funding of long-term care and medico-social policies regarding elderly people. GeNeDis 2016 takes place in Sparta, Greece, 20-23 October, 2016. This volume focuses on the sessions that address geriatrics.